Skip to main content

Table 2 IC50 values and sensitization ratio of conventional chemotherapeutic drugs and its combinations with MF towards human colorectal cancer cell lines SW1116 and SW837

From: Methylferulate from Tamarix aucheriana inhibits growth and enhances chemosensitivity of human colorectal cancer cells: possible mechanism of action

Single and combined treatment with chemotherapeutic drugs and MF SW1116
IC50 (M)a Sensitization ratiob Pc values
CPT (128× 10−11- 1× 10−4 M) 2.0 × 10−5 -  
CPT (128× 10−11 - 1× 10−4 M) + MF (1.5 mM) 21 × 10−8 95.0 0.025
5FU (89.6× 10−10- 0.7× 10−3 M) 8.83 × 10−6 -  
5FU (89.6× 10−10- 0.7× 10−3 M) + MF (1.5 mM) 84 × 10−10 1051 0.025
DOX (110× 10−12 - 0.86× 10−5 M) 0.43 × 10−4 -  
DOX (110× 10−12 - 0.86× 10−5) + MF (1.5 mM) 3.44 × 10−7 125 0.081
TAX (94× 10−11- 1.47× 10−4 M) 1.47 × 10−4 -  
TAX (94× 10−11- 1.47× 10−4 M) + MF (1.5 mM) 5.72 × 10−6 26 0.183
VBL (3.84× 10−11 - 0.03× 10−4 M) 0.22 × 10−8 -  
VBL (3.84× 10−11 - 0.03× 10−4 M) + MF (1.5 mM) 3.52 × 10−11 62.55 0.326
VCR (3.84× 10−11 - 0.03× 10−4 M) 0.4 × 10−8 -  
VCR (3.84× 10−11 - 0.03× 10−4 M) + MF (1.5 mM) 3.15 × 10−11 254 0.079
ETP (5.12× 10−10 - 0.04× 10−3M) 1.19 × 10−6 -  
ETP (5.12× 10−10 - 0.04× 10−3M) + MF (1.5 mM) 5.4 × 10−10 2204 0.026
ELP (2.56× 10−10 - 0.02× 10−3M) 0.06 × 10−4 -  
ELP (2.56× 10−10 - 0.02× 10−3M) + MF (1.5 mM) 1.3 × 10−9 4615 0.001
AMS (1.28× 10−10- 0.01× 10−3M) 0.013 × 10−3 -  
AMS (1.28× 10−10- 0.01× 10−3M) + MF (1.5 mM) 0.2 × 10−7 650 0.001
HHG (25.6× 10−12 – 0.2× 10−5M) 2.0 × 10−7 -  
HHG (25.6× 10−12 – 0.2× 10−5M) + MF (1.5 mM) 3 × 10−9 67 0.010
Single and combined treatment with chemotherapeutic drugs and MF SW837
IC50 (M)a Sensitization ratiob Pc values
CPT (128× 10−11- 1× 10−4 M) 5 × 10−5 -  
CPT (128 × 10−11- 1× 10−4 M) + MF (1.5 mM) 4 × 10−6 12.5 0.012
5FU (89.6× 10−10- 0.7× 10−3 M) 0.7 × 10−3 -  
5FU (89.6× 10−10- 0.7× 10−3 M) + MF (1.5 mM) 2.6 × 10−5 269 0.001
DOX (110× 10−12 - 0.86× 10−5 M) 3.44 × 10−6 -  
DOX (110× 10−12 - 0.86× 10−5) + MF (1.5 mM) 27.5 × 10−8 12.5 0.005
TAX (94× 10−11- 1.47× 10−4 M) 1.47 × 10−4 -  
TAX (94× 10−11- 1.47× 10−4 M) + MF (1.5 mM) 5.86 × 10−6 25 0.045
VBL (3.84× 10−11 - 0.03× 10−4 M) 0.11 × 10−6 -  
VBL (3.84× 10−11 - 0.03× 10−4 M) + MF (1.5 mM) 0.44 × 10−8 25 0.060
VCR (3.84× 10−11 - 0.03× 10−4 M) 0.2 × 10−7 -  
VCR (3.84× 10−11 - 0.03× 10−4 M) + MF (1.5 mM) 2.4 × 10−9 8.33 0.119
ETP (5.12× 10−10 - 0.04× 10−3M 0.18 × 10−4 -  
ETP (5.12× 10−10 - 0.04× 10−3M) + MF (1.5 mM) 0.51 × 10−6 35 0.003
ELP (2.56× 10−10 - 0.02× 10−3M) 0.02 × 10−3 -  
ELP (2.56× 10−10 - 0.02× 10−3M) + MF (1.5 mM) 0.32 × 10−7 625 0.001
HHG (25.6× 10−12 – 0.2× 10−5M) 0.6 × 10−6 -  
HHG (25.6× 10−12 – 0.2× 10−5M) + MF (1.5 mM) 2.25 × 10−8 27 0.012
  1. aThe data are based on the mean of absorbance measurements from three independent experiments
  2. bSensitization ration = IC50 of drug / IC50 of drug + MF
  3. cP Value for the combined treatment with drug and MF vs. drug alone